Pfizer announced its balance sheet for the fourth quarter of 2022.
In the statement, it was stated that the revenue of the company in the last quarter of last year increased by 2 percent compared to the same period of 2021, reaching 24.3 billion dollars.
In the statement, it was stated that Pfizer’s revenue increased by 23 percent compared to the previous year in 2022 and reached 100.3 billion dollars, and it was mentioned that this number was the highest income of the company.
In the statement, it was stated that the company’s 2023 revenues are expected to decrease in the middle of 29 percent to 33 percent compared to last year, and it was noted that this year’s revenue claim is in the middle of 67 billion dollars and 71 billion dollars.
In the statement, it was stated that the revenues of the Kovid-19 vaccine developed with BioNTech are expected to decrease by 64 percent to 13.5 billion dollars, and the revenues of the Paxlovid antiviral drug to 8 billion dollars with a decrease of 58 percent.
